European Parliament Library

The economics of diseases and cures, Randall Waechter, editor

Label
The economics of diseases and cures, Randall Waechter, editor
Language
eng
Illustrations
illustrations
Index
index present
Literary Form
non fiction
Main title
The economics of diseases and cures
Nature of contents
dictionaries
Oclc number
1250260753
Responsibility statement
Randall Waechter, editor
Series statement
Economic Issues, Problems and Perspectives
Summary
"This book examines the process of cure discovery and the economic impact of cures across varying diseases. It is the first time anyone has attempted to examine the [economic] returns across a wide spectrum of disease categories, using a common frame of reference"--, Provided by publisher
Table Of Contents
Intro -- Contents -- Foreword -- Acknowledgments -- List of Acronyms -- Section A. Background and Measures -- Chapter 1 -- The Economics of Diseases and Cures -- Different Levels of Cures: Functional vs. Definitive -- Measuring the Economic Impact of Cures: Cost Strategy vs. Cures Strategy -- The Diffusion of Cures -- The Value of Case Studies -- References -- Chapter 2 -- Tools and Assumptions -- Data Sources -- Timelines -- Disease Categorization -- Cure Categorization -- Measures used to Assess the Value of Cures -- Years of Potential Life Lost (YPLL) -- Quality-Adjusted Life Years (QALY) -- Disability-Adjusted Life Years (DALY) -- Cure Impact -- Calculation Assumptions -- References -- Section B. Infectious Diseases -- Chapter 3 -- Acquired Immunodeficiency Syndrome (AIDS/HIV) -- Disease Category -- Disease Identification, Description, and Diagnostic Criteria -- Disease Etiology (Cause) -- Current Prevalence/Incidence -- Estimated Undiagnosed and At-Risk -- Disease Impact - Years of Potential Life Lost (YPLL) -- Disease Impact - Disability Adjusted Life Years (DALY) -- History of the Disease and Breakthroughs -- Current Cure Status -- Future Cure Obstacles -- Research Development and Treatment Costs -- HIV Cures: Anti-Retroviral Therapy (ART) -- Cure Category -- Cure Identification/Description -- Cure History -- Cure Science: Breakthroughs/Obstacles -- Cure Science: Future Obstacles -- Number of Patients Currently Being Treatment -- Number of Patients Requiring Treatment -- Impact of Treatment on Years of Potential Life Lost (YPLL) -- Impact of Treatment on Disability-Adjusted Life Years (DALY/QALY) -- Cost of Treatment Using ART per Patient -- Cost of Lifetime Treatment Using ART -- Economic Impact - Value of Life Added -- HIV Cures - Vaccination -- Cure Category -- Cure History -- Cure Science/Cure Obstacles -- Phase I TrialsPhase II Trials -- Phase III Trials -- References -- Chapter 4 -- Influenza -- Disease Category -- Disease Description, Diagnosis, and Background -- Disease Etiology (Cause) -- Current Prevalence/Incidence -- Estimated Undiagnosed/At-Risk -- Disease Impact - Years of Potential Life Lost (YPLL) -- Disease Impact - Disability Adjusted Life Years (DALY) -- History of the Disease and Breakthroughs -- Current Cure Status -- Research, Development and Treatment Costs -- Influenza Cures: Vaccinations -- Cure Category -- Cure Identification/Description -- Cure History -- Cure Science: Breakthroughs/Obstacles -- Cure Science/Future Cure Obstacles and Targets -- Number of Patients Currently Being Treated -- Number of People Requiring Treatment -- Impact of Treatment on Years of Potential Life Lost (YPLL) -- Impact of Treatment on Disability-adjusted Life Years (DALY/QALY) -- Average Annual Total/Lifetime Cost of Vaccinations -- Economic Impact - Value of Life Added -- Economic Impact - Value of Reduction in DALYs/Increase in QALYs -- Influenza Cures: Antivirals -- Cure Category -- Cure Identification/Description -- Cure History -- Cure Science: Breakthroughs/Obstacles -- Cure Science/Future Cure Obstacles and Targets -- Number of Patients Being Treated -- Number of Patients Requiring Antiviral Treatment -- Impact of Antivirals on Years of Potential Life Lost (YPLL) -- Impact of Antivirals on Disability-adjusted Life Years (DALYs/QALYs) -- Average Annual Cost of Antivirals -- Average Lifetime Cost of Antivirals -- Economic Impact - Value of Life Added -- Economic Impact - Value of Reduction in DALYs/Increase in QALYs -- References -- Chapter 5 -- Poliomyelitis -- Disease Category -- Disease Identification, Description, and Diagnostic Criteria -- Disease Etiology (Cause) -- Current Prevalence/Incidence -- Estimated Undiagnosed/At-RiskDisease Impact - Years of Potential Life Lost (YPLL) -- Disease Impact - Disability Adjusted Life Years (DALY) -- History of Disease and Breakthroughs -- Current Cure Status -- Future Cure Obstacles -- Research Development and Treatment Costs -- Polio Cures: Vaccines -- Cure Category -- Cure Identification/Description/Diagnostic Criteria -- Cure History -- Cure Science: Breakthroughs/Obstacles -- Cure Science: Future Obstacles and Targets -- Number of Patients Currently Being Treated -- Number of Patients Requiring Treatment -- Impact of Polio Vaccine on Years of Potential Life Lost (YPLL) -- Impact of Polio Vaccine on Disability Adjusted Life Years (DALYs/QALYs) -- Cost of Vaccination -- Economic Impact - Value of Life Added -- Economic Impact - Value of Years lived without Disability -- References -- Chapter 6 -- SARS-CoV-2 -- Disease Category -- Disease Identification, Description, and Diagnostic Criteria -- Transmission and Symptomatology -- Testing -- Disease Etiology (Cause) -- Current Prevalence/Incidence -- Estimated Undiagnosed/At-Risk -- Hospitalizations -- Mortality -- Disease Impact - Years of Potential Life Lost (YPLL) -- Disease Impact- Disability Adjusted Life Years (DALY) -- History of the Disease and Breakthroughs -- Current Cure Status -- Research, Development and Treatment Cost -- SARS-CoV-2 Cures: Behavioral Interventions -- Cure Category -- Cure Identification/Description -- Cure History -- Black Death in 1347 -- Spanish Flu in 1918 -- Cure Science: Breakthroughs/Obstacles -- Cure Science/Future Cure Obstacles and Targets -- Number of Patients Currently Being Treated/Requiring Treatment -- Impact of Treatment on Years of Potential Life Lost (YPLL) -- Impact of Treatment on Disability-adjusted Life Years (DALY/QALY) -- Cost of Treatment -- Economic Impact- Value Life Added -- SARS-CoV-2 Cures: Vaccinations -- Cure CategoryCure Identification/Description -- Cure History -- Cure Science: Breakthroughs/Obstacles -- Cure Science/Future Cure Obstacles and Targets -- Number of Patients Currently Being Treated -- Number of People Requiring Treatment -- Impact of Treatment on Years of Potential Life Lost (YPLL) -- Impact of Treatment on Disability-Adjusted Life Years (DALY/QALY) -- Cost of Treatment -- Economic Impact - Value Life Added -- Economic Impact - Value of Reduction in DALYs/Increase QALYs -- SARS-CoV-2 Cures: Antiviral Medications -- Cure Category -- Cure Identification/Description -- Cure History -- Cure Science: Breakthroughs/Obstacles -- Cure Science: Future Obstacles and Targets -- Number of Patients Being Treated and Requiring Antiviral Treatment -- Impact of Antivirals on Years of Potential Life Lost (YPLL) -- Impact of Antivirals on Disability-Adjusted Life Years (DALYs/QALYs) -- Cost of Treatment -- Economic Impact - Value of Life Added -- Economic Impact - Value of Reduction in DALYs/Increase in QALYs -- SARS-CoV-2 Cures: Immunosuppression Medications -- Cure Category -- Cure Identification/Description -- Cure History -- Cure Science: Breakthroughs/Obstacles -- Cure Science/Future Cure Obstacles and Targets -- Number of Patients Currently Being Treated and Requiring Treatment -- Impact of Immunosuppressants on Years of Potential Life Lost (YPLL) -- Impact of Immunosuppressants on Disability-Adjusted Life Years (DALY/QALY) -- Cost of Treatment -- Economic Impact- Value Life Added -- Economic Impact-Value of Reduction in DALYs/Increase QALYs -- SARS-CoV-2 Cures: Convalescent Plasma Therapy -- Cure Category -- Cure Identification/Description -- Cure History -- Cure Science: Breakthroughs/Obstacles -- Cure Science/Future Cure Obstacles and Targets -- Number of Patients Currently Being Treated/Requiring TreatmentImpact of Treatment on Years of Potential Life Lost (YPLL) -- Impact of Treatment on Disability-Adjusted Life Years (DALY/QALY) -- Cost of Treatment -- Economic Impact- Value Life Added -- Economic Impact- Value of Reduction in DALYs/Increase QALYs -- References -- Section C. Chronic Diseases -- Chapter 7 -- Alzheimer's Disease -- Disease Category -- Disease Identification, Description, and Diagnostic Criteria -- Disease Etiology (Causes) -- Current Prevalence/Incidence -- US Prevalence -- US Incidence -- Estimated Undiagnosed/At-Risk -- Disease Impact - Years of Potential Life Lost (YPLL) -- Disease Impact - Disability Adjusted Life Years (DALYs) -- Economic Impact - Years of Potential Life Lost (YPLL) -- Economic Impact - Disability Adjusted Life Years (DALYs) -- History of the Disease and Breakthroughs -- Current Cure Status -- Future Cure Obstacles -- Research Development and Treatment Costs -- References -- Chapter 8 -- Cardiovascular Disease -- Disease Category -- Disease Identification/Description/Diagnostic Criteria -- Disease Etiology (Cause) -- Disease Prevalence/ Incidence -- Estimated Undiagnosed/ At-Risk -- Disease Impact - Years of Potential Life Lost (YPLL) -- Disease Impact - Disability Adjusted Life Years (DALY) -- Current Cure Status -- Future Cure Obstacles -- Research Development and Treatment Costs -- Average Cost of Treating the Disease -- Economic Impact - YPLL -- Cardiovascular Disease Cures: Overview -- Cardiovascular Disease Cures: Heart Surgery -- Cure Category -- Cure Identification/ Description -- Cure History and Science: Breakthroughs/ Obstacles -- Number of Patients Being Treated -- Impact on Treatment on Years of Potential Life Lost (YPLL) -- Average Cost of Cure Per Patient -- Economic Impact - Value of Increased Years of Life Lived -- Cardiovascular Disease Cures: Angioplasty -- Cure CategoryCure Identification/ Description
Classification
Content
Other version
Mapped to

Incoming Resources

Outgoing Resources